argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
November 01, 2023 02:00 ET
|
argenx SE
Long-term clinical trial and real-world data illustrate VYVGART® drives consistent, repeatable and clinically meaningful responses, including minimal symptom expression (MSE) in generalized...
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
October 31, 2023 02:00 ET
|
argenx SE
$329 million in third quarter global net product salesOn track to submit VYVGART® Hytrulo sBLA for CIDP by year-end 2023 Results from the ADVANCE-IV study published in The Lancet Management to host...
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
October 24, 2023 01:00 ET
|
argenx SE
October 24, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis
September 21, 2023 01:00 ET
|
argenx SE
VYVGARTⓇ is the first-and-only neonatal Fc receptor (FcRn) blocker authorized for sale in Canada Approval based on the positive Phase 3 ADAPT trial (p<0.0001) showing 68% of VYVGART-treated...
argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis
September 15, 2023 01:00 ET
|
argenx SE
Positive opinion based on Phase 3 ADAPT-SC study demonstrating noninferior total IgG reduction at day 29 with subcutaneously (SC) administered efgartigimod, compared to intravenous (IV)...
argenx to Present at Upcoming Investor Conferences
August 30, 2023 01:00 ET
|
argenx SE
August 30, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Reports Half Year 2023 Financial Results and Provides Second Quarter Business Update
July 27, 2023 01:00 ET
|
argenx SE
$269 million in second quarter VYVGART® (efgartigimod alfa-fcab) global net product sales VYVGART® Hytrulo now available in the U.S. with first vials shipped in JulyGlobal VYVGART expansion...
argenx announces closing of global offering
July 24, 2023 16:30 ET
|
argenx SE
Regulated information – Inside information July 24, 2023, 4:30 PM ETJuly 24, 2023, 10:30 PM CET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023 01:00 ET
|
argenx SE
July 20, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023 17:58 ET
|
argenx SE
Regulated information — Inside information July 19, 2023, 11:58 PM CETJuly 19, 2023, 5:58 PM ET Amsterdam, the Netherlands — argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...